Drug Profile
S 110483
Alternative Names: S-110483Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Class Analgesics; Anti-inflammatories; Antirheumatics
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Rheumatic disorders
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Rheumatic-disorders in Japan (PO)
- 09 Jan 2018 S 110483 is available for licensing as of 09 Jan 2018. http://www.kaken.co.jp/english/business/license.html
- 03 Nov 2017 Preclinical trials in Rheumatic disorders in Japan (PO)